ESMO 2014 - Gastrointestinal and Head & Neck Cancer
Cetuximab, Fluorouracil, and Cisplatin, with/without Docetaxel, in Recurrent or Metastatic Head and Neck Cancer
The AIO 1108 study was an open-label, randomized, multicenter trial that evaluated the efficacy and tolerability of cetuximab, fluorouracil, cisplatin (PFC) plus docetaxel (PFCD) versus a standard PFC regimen in patients with recurrent or metastatic head and neck squamous-cell carcinoma (SCC).
Recurrent or metastatic head and neck squamous-cell carcinoma (SCC) is associated with a poor prognosis, and the treatment options are limited in this disease setting, highlighting the need for novel treatment strategies.
Association of HPV and p16 Status with Cetuximab plus Radiotherapy in Locally Advanced Head and Neck Cancer
The randomized phase 3 IMCL-9815 trial demonstrated that the addition of cetuximab to radiotherapy improved locoregional control (LRC) and overall survival (OS) in patients with locoregionally advanced squamous-cell carcinoma (SCC) of the head and neck.
Recurrent and metastatic head and neck squamous-cell carcinoma (SCC) is associated with a poor prognosis, and the treatment options are limited in this disease setting, highlighting the need for novel treatment strategies.
CALGB/SWOG 80405: FOLFIRI or mFOLFOX6 plus Bevacizumab or Cetuximab for Patients with Metastatic Colorectal Cancer
The standard first-line treatments for metastatic colorectal cancer (mCRC) is bevacizumab or cetuximab combined with chemotherapy—either fluoropyrimidine, leucovorin, irinotecan (FOLFIRI) or fluoropyrimidine, leucovorin, oxaliplatin (mFOLFOX6); however, their relative efficacy and safety are unknown.
The phase 3 CALGB/SWOG 80405 clinical trial analyzed the clinical benefit of the addition of cetuximab or bevacizumab to first-line chemotherapy with FOLFOX or FOLFIRI in KRAS wild-type (codons 12 and 13) in 1137 patients with metastatic colorectal cancer.
Although both cetuximab and bevacizumab have separately demonstrated improvements in clinical outcomes in patients with metastatic colorectal cancer (mCRC) when added to first-line chemotherapy regimens, their comparative efficacies in combination with fluorouracil, folinic acid, and irinotecan (FOLFIRI) are unknown.
The CRYSTAL study demonstrated that the addition of cetuximab to first-line chemotherapy significantly improved clinical outcomes, specifically for patients with RAS wild-type metastatic colorectal cancer (mCRC).
The phase 3 New EPOC study randomized patients with resectable or suboptimally resectable colorectal liver metastases (CRLM) and KRAS exon 2 wild-type disease status to receive chemotherapy with or without the anti–epidermal growth factor receptor (EGFR) monoclonal antibody cetuximab (Bridgewater J, et al. EPOC study. ESMO 2014: Abstract 542P).
FOLFOXIRI plus Bevacizumab or Anti-EGFR Antibodies in RAS/BRAF Wild-Type Metastatic Colorectal Cancer
Monoclonal antibodies (MoAbs) targeting vascular endothelial growth factor (VEGF) or epidermal growth factor receptor (EGFR) in combination with first-line doublet chemotherapy have demonstrated considerable clinical activity in metastatic colorectal cancer (mCRC).
Page 1 of 2
Results 1 - 10 of 19
Results 1 - 10 of 19